An exploratory analysis of patients receiving an SGLT2 inhibitor at baseline who were treated with finerenone (n = 124) in the FIDELIO-DKD trial reported numerically lower rates of hyperkalemia-related AEs and greater reductions in UACR compared to those not receiving an SGLT2 inhibitor at baseline (n = 2,703).32 This evidence concerns the gene SLC5A2 and Hyperkalemia.